Research programme: RNAi therapeutics - Alnylam/University of California San Francisco

Drug Profile

Research programme: RNAi therapeutics - Alnylam/University of California San Francisco

Alternative Names: GNAQ - Alnylam

Latest Information Update: 05 May 2011

Price : $50

At a glance

  • Originator Alnylam Pharmaceuticals; University of California at San Francisco
  • Class Small interfering RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Malignant melanoma

Most Recent Events

  • 05 May 2011 No development reported - Preclinical for Malignant melanoma in USA (Parenteral)
  • 15 Dec 2008 Preclinical trials in Malignant melanoma in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top